Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a research report report published on Thursday morning.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other research firms have also recently weighed in on KURA. Wedbush started coverage on Kura Oncology in a research note on Wednesday, December 20th. They set an outperform rating and a $19.00 target price on the stock. BidaskClub cut Kura Oncology from a hold rating to a sell rating in a research note on Tuesday, January 9th. Oppenheimer set a $18.00 target price on Kura Oncology and gave the company a buy rating in a research note on Monday, December 11th. Citigroup lifted their target price on Kura Oncology from $15.00 to $19.00 and gave the company a buy rating in a research note on Thursday, November 9th. Finally, Cann reaffirmed a buy rating and set a $17.50 target price on shares of Kura Oncology in a research note on Monday, December 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Kura Oncology currently has an average rating of Buy and a consensus target price of $18.08.
Kura Oncology (NASDAQ:KURA) opened at $19.00 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. Kura Oncology has a 12 month low of $5.90 and a 12 month high of $21.00. The firm has a market capitalization of $574.10 and a PE ratio of -12.26.
Several hedge funds and other institutional investors have recently made changes to their positions in KURA. Candriam Luxembourg S.C.A. bought a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $8,073,000. BlackRock Inc. grew its stake in shares of Kura Oncology by 49.1% in the 4th quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock valued at $23,331,000 after buying an additional 502,296 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Kura Oncology in the 3rd quarter valued at approximately $2,884,000. State Street Corp bought a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $1,394,000. Finally, Northern Trust Corp grew its stake in shares of Kura Oncology by 939.3% in the 2nd quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after buying an additional 133,293 shares in the last quarter. 62.96% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/12/kura-oncology-kura-stock-rating-upgraded-by-zacks-investment-research.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Get a free copy of the Zacks research report on Kura Oncology (KURA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.